NasdaqHealth CarePharmaceutical PreparationsREDWOOD CITY, CA

Bolt Biotherapeutics, Inc. BOLT

Ask your AI

Estimated market cap $15.85M2.61M shares, shares as of Nov 6, 2026CIK 1641281

Insider trades, 12 mo

5 buys · 9 sells

$128.4K sold, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

12.3% of shares · 3 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in Bolt Biotherapeutics, Inc.'s latest quarterly report, compared with the one before.

Filed Nov 13, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Bolt Biotherapeutics, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

14 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Recent insider trades

Coastlands Capital LP 10% owner	Nov 9 Form 4 ↗	Buy	+$319.0K 50,000 sh @ $6.38	-5.7%
William P. Quinn President, CEO and CFO, Director	Sep 18 Form 4 ↗	Sale	−$29.6K 9,132 sh @ $3.24	+71.7%
Grant Yonehiro Chief Operating Officer	Sep 18 Form 4 ↗	Sale	−$22.2K 6,850 sh @ $3.24	+71.7%
Sarah Nemec Senior VP, Finance and PAO	Sep 18 Form 4 ↗	Sale	−$13.2K 4,077 sh @ $3.24	+71.7%
Grant Yonehiro Chief Operating Officer	Sep 17 Form 4 ↗	Sale	−$16.3K 4,909 sh @ $3.32	+82.8%

All BOLT insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

319,721 shares

16 funds report BOLT. Values checked against market prices.

Funds own 31% of shares (Q2 2026)

23 funds hold the stock.

Q3 2026: 12% · 5,560 of ~8,900 funds reported so far

Q2 202546%
Q3 202542%
Q4 202531%
Q1 202632%
Q2 202631%
Q3 2026 (so far)12%

Q3 2026. 0 new, 3 added to, 5 trimmed, 7 exited since Q2 2026.

Top 13F holders
#
1	Renaissance Technologies LLC 13F ↗	92,925	$342.0K	-5.8%
2	Vivo Capital, LLC 13F ↗	72,414	$266.5K	unchanged
3	T3 Companies, LLC 13F ↗	38,000	$139.8K	unchanged
4	Pfizer Inc 13F ↗	31,305	$112.1K	unchanged
5	Nano Cap New Millennium Growth Fund LP 13F ↗	27,500	$101.2K	unchanged
6	Geode Capital Management, LLC 13F ↗	15,797	$58.1K	-17.4%
7	Vanguard Fiduciary Trust Co 13F ↗	15,533	$57.2K	+401.9%
8	BlackRock, Inc. 13F ↗	9,711	$35.7K	unchanged
9	Vanguard Capital Management LLC 13F ↗	7,060	$26.0K	unchanged
10	Nan Fung Group Holdings Ltd 13F ↗	5,000	$18.4K	unchanged

Download CSV Every fund that holds BOLT, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Bolt Biotherapeutics, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Bolt Biotherapeutics, Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q2 2025	25	—	887,531	$5.1M
Q3 2025	24	-1	804,078	$4.3M
Q4 2025	21	-3	602,538	$3.3M
Q1 2026	24	+3	613,252	$2.5M
Q2 2026	23	-1	596,527	$2.3M
Q3 2026	16	-7	319,721	$1.2M

Each point is a quarter-end, from Q2 2025 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (097702203). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q2 2025) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes6 in 12 mo 8-K events3 in 90 days Patents5 patents granted Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials1 active IPO history1 registration Layoff notices1 notice · 38 jobs Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Bolt Biotherapeutics, Inc.
Address: 900 CHESAPEAKE DRIVE, REDWOOD CITY, CA 94063
Phone: 650-665-9295
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company, emerging growth company
Incorporated in: DE
Listed as: BOLT (Nasdaq)
Former names: Bolt Therapeutics, Inc. (until 2015)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$6.08+$0.17 (+2.88%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $3.98 · High $6.59Nov 13, 2026

Aug 13, 2026Low $3.18 · High $6.59Nov 13, 2026

Nov 13, 2025Low $3.18 · High $7.09Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.